China Medical System Holdings Ltd. Announces Collaboration Agreements for Innovative Biologic Products
I'm PortAI, I can summarize articles.
China Medical System Holdings Ltd. has signed collaboration agreements for two innovative biologic products: Vecantoxatug Injection and Silevimig Injection. These agreements aim to enhance the company's business performance by leveraging synergies with its existing portfolio. The terms are deemed fair and reasonable by the company's directors, and the collaborating entity, Genrix Bio, is an independent third party. The transaction does not qualify as a connected or notifiable transaction under Hong Kong Stock Exchange Listing Rules.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments